Association of N-terminal pro C-type natriuretic peptide and endothelin-1 levels with the risk of cardiovascular complications in arterial hypertension six months after COVID-19

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background. Despite the significant decline in the prevalence of COVID-19 around the world, the consequences of the pandemic on the health and quality of life of patients according to the data from clinical studies will remain a leading public health issue for a long time.

Objective. Dynamic evaluation and analysis of the N-terminal pro C-type natriuretic peptide (NUPC) and endothelin-1 (ET-1) levels in patients six months after COVID-19 against the background of arterial hypertension (AH), depending on the stratification of cardiovascular risk in AH.

Methods. 45 hypertensive patients with confirmed diagnosis of coronavirus infection COVID-19 (virus identified) who were treated in an infectious diseases hospital were examined. Determination of the NUPC and ET-1 levels in blood serum samples was carried out using the enzyme immunoassay method. Biomarker levels were determined twice – on the first day of admission to the hospital and six months after discharge. Cardiovascular risk in AH was also assessed twice – on the first day of admission to the hospital and six months after discharge.

Results. Analysis of the NUPC and ET-1 levels on hospital admission between patients with moderate risk (risk 2) and high risk (risk 3) did not show statistically significant differences (P=0.487, P=0.821, respectively). Six months after COVID-19, in hypertensive patients with very high risk (risk 4), the levels of both ET-1 and NUPC were statistically significantly higher than in patients with high risk (risk 3) (P=0.012 and P<0.001, respectively). An increase in cardiovascular risk in AH six months after discharge from hospital was observed in 15 (33.3%) patients, and in 30 (66.7%) patients, cardiovascular risk in AH remained the same. In hypertensive patients who experienced an increase in cardiovascular risk six months after discharge from hospital for COVID-19, the levels of both ET-1 and NUPC were statistically significantly higher compared with patients who cardiovascular risk in AH did not change (P=0.01 and P<0.001, respectively).

Conclusion. According to the results of the study, it was found that the highest levels of both ET-1 and NUPC six months after discharge from the hospital were in patients with a very high risk (risk 4) and in patients who had an increase in cardiovascular risk in AH.

Texto integral

Acesso é fechado

Sobre autores

A. Shuvalova

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Email: gilti2@yandex.ru
ORCID ID: 0009-0003-1912-7300
Rússia, Astrakhan

T. Prokofieva

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Email: gilti2@yandex.ru
ORCID ID: 0000-0002-3260-2677
Rússia, Astrakhan

O. Polunina

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Email: gilti2@yandex.ru
ORCID ID: 0000-0001-8299-6582
Rússia, Astrakhan

Ekaterina Polunina

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Autor responsável pela correspondência
Email: gilti2@yandex.ru
ORCID ID: 0000-0002-3679-432X

Dr. Sci. (Med.), Professor of the Department of Internal Medicine Faculty of Pediatrics

Rússia, Astrakhan

Bibliografia

  1. Huang L., Li X., Gu X., et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10(9):863–76. doi: 10.1016/S2213-2600(22)00126-6.
  2. Ordinola Navarro A., Cervantes-Bojalil J., Cobos Quevedo O.J., et al. Decreased quality of life and spirometric alterations even after mild-moderate COVID-19. Respir Med. 2021;181:106391. doi: 10.1016/j.rmed.2021.106391.
  3. Чичкова В.В., Шаповалова М.А., Чичкова М.А. и др. Организация амбулаторной помощи пациентам с сахарным диабетом в условиях пандемии COVID-19 с применением телемедицинских технологий. Сахарный диабет. 2023;26(4):334–42. [Chichkova V.V., Shapovalova M.A., Chichkova M.A., et al. Organization of outpatient care for patients with diabetes mellitus in the context of the COVID-19 pandemic using telemedicine technologies. Diab Mellit. 2023;26(4):334–42. (In Russ.)]. doi: 10.14341/DM13019.
  4. Канорский С.Г. Постковидный синдром: распространенность и патогенез органных поражений, направления коррекции. Систематический обзор. Кубанский научный медицинский вестник. 2021;28(6):90–116. [Kanorskii S.G. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Nauch Med Vestn. 2021;28(6):90–116. (In Russ.)]. doi: 10.25207/1608-6228-2021-28-6-90-116.
  5. Бунова С.С., Охотникова П.И., Скирденко Ю.П. и др. COVID-19 и сердечно-сосудистая коморбидность: поиск новых подходов к снижению смертности. Кардиоваскулярная терапия и профилактика. 2021;20(4):2953. [Bunova S.S., Okhotnikova P.I., Skirdenko Yu.P., et al. COVID-19 and cardiovascular comorbidity: novel approaches to reduce mortality. Cardiovasc Ther Prevent. 2021;20(4):2953. (In Russ.)]. doi: 10.15829/1728- 8800-2021-2953.
  6. Munblit D., Nicholson T., Akrami A., et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10(7):715–24. doi: 10.1016/S2213-2600(22)00169-2.
  7. Muhamad S.A., Ugusman A., Kumar J., et al. COVID-19 and hypertension: The what, the why and the how. Front Physiol. 2021;12:665064. doi: 10.3389/fphys.2021.665064.
  8. Shrestha D.B., Budhathoki P., Raut, S., et al. New-Onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021;10:275–87. doi: 10.5501/wjv.v10.i5.275.
  9. Daugherty S.E., Guo Y., Heath K., et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.
  10. Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–59. doi: 10.1001/jama.2020.6775.
  11. Чазова И.Е., Блинова Н.В., Невзорова В.А. и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: артериальная гипертония и COVID-19. Системные гипертензии. 2020;17(3): 35–41. [Chazova I.E., Blinova N.V., Nevzorova V.A., et al. Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Syst Hypertens. 2020;17(3):35–41. (In Russ.)]. doi: 10.26442/2075082X.2020.3.200362.
  12. Елфимов Д.А., Елфимова И.В., Хамитова И.Р. и др. Некоторые особенности течения артериальной гипертонии у пациентов, перенесших новую коронавирусную инфекцию (COVID-19). Медицинская наука и образование Урала. 2021;2:75–9. [Elfimov D.A., Elfimova I.V., Khamitova I.R., et al. Some features of the course of arterial hypertension in patients undergoing a new coronavirus infection (COVID-19). Med Sci Educat Urals. 2021;2:75–9. (In Russ.)]. doi: 10.36361/1814-8999-2021-22-2-75-79.
  13. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3.
  14. Gallo G., Calvez V., Savoia C. Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Press. Cardiovasc Prev. 2022;29(2):115–23. doi: 10.1007/s40292-022-00506-9.
  15. Uysal B., Akca T., Akacı O., et al. The Prevalence of Post-COVID-19 Hypertension in Children. Clin Pediatr (Phila). 2022;61(7):453–60. doi: 10.1177/00099228221085346.
  16. Chioh F.W., Fong S.W., Young B.E., et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife. 2021;10:e64909. doi: 10.7554/eLife.64909.
  17. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9(3):e14726. doi: 10.14814/phy2.14726.
  18. Яровая Д.В., Башкина О.А., Красилова Е.В. Влияние коронавирусной инфекции на маркеры эндотелиальной дисфункции у детей при патологии почек. Человек и его здоровье. 2023;26(1):4–8. [Yarovaya D.V., Bashkina O.A., Krasilova E.V. Effects of coronavirus infection on markers of endothelial dysfunction in children with renal pathology. Hum Their Health. 2023;26(1):4–8 (In Russ.)]. doi: 10.21626/vestnik/2023-1/01.
  19. Голивец Т.П., Дубоносова Д.Г., Осипова О.А. и др. Эффекты эндотелина-1 в развитии и прогрессировании метаболического синдрома и других социально значимых неинфекционных заболеваний (Обзор литературы). Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2017;19(268):5–19. [Golivets T.P., Dubonosova D.G., Osipova О.А., et al. The effects of endothelin 1 in the development and progression of metabolic syndrome and socially significant non-communicable diseases (review of literature). Med Sci Educat Sci Bull Belgorod State Univer. Series: Medicine. Pharmacy. 2017;19(268):5–19. (In Russ.)].
  20. Idris-Khodja N., Ouerd S., Mian M.O.R., et al. Endothelin-1 Overexpression Exaggerates Diabetes-Induced Endothelial Dysfunction by Altering Oxidative Stress. Am J Hypertens. 2016;29(11):1245–51. doi: 10.1093/ajh/hpw078.
  21. Moyes A.J., Hobbs A.J. C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci. 2019;8;20(9):2281. doi: 10.3390/ijms20092281.
  22. Воронина Л.П. Генетические, биохимические и функциональные маркеры состояния вазорегулярующей функции эндотелия. Сибирский медицинский журнал (Иркутск). 2011;102(3):29–31. [Voronina L.P. Genetic, biochemical and functional markers of condition of vasoregulating function of endothelium. Sibir Med J (Irkutsk). 2011;102(3):29–31. (In Russ.)].
  23. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Министерства здравоохранения Российской Федерации (версии 13–14). [Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Ministry of Health of the Russian Federation (versions 13–14). (In Russ.)]. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf
  24. Клинические рекомендации «Артериальная гипертензия у взрослых», год утверждения 2020. [Clinical guidelines “Arterial hypertension in adults”, year of approval 2020. (In Russ.)]. URL: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf
  25. Наследов А. SPSS 19: профессиональный статистический анализ данных. СПб., 2011. 400 с. [Nasledov A. SPSS 19: professional statistical data analysis. 2011. 400 р. (In Russ.)].
  26. Willems L.H., Nagy M., Ten Cate H., et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res. 2022;209:106–14. doi: 10.1016/j.thromres.2021.11.027.
  27. Abraham G.R., Kuc R.E., Althage M., et al. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022;167:92–6. doi: 10.1016/j.yjmcc.2022.03.007.
  28. Bojti I., Przewosnik A.S., Luxenburger H., et al. Decreased level of serum NT-proCNP associates with disease severity in COVID-19. Respir Res. 2023;24(1):174. doi: 10.1186/s12931-023-02469-4.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2024

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies